Signet Therapeutics Named to 2026 Future Healthcare 100 List for Innovative Health Services and Industrial Chain Solutions

Recently, Vbdata officially released the "2026 Future Healthcare 100 Strong" list. Signet Therapeutics, with its pioneering innovation capabilities in the field of "organoids + AI" for new drug development, rapid clinical advancement of core pipelines, and outstanding growth potential, successfully...Selected as one of the TOP 100 in the 2026 Future Healthcare 100 Strong·Innovative Health Services and Industry Chain Services List.

The Future Healthcare 100 list is a highly credible and authoritative selection in China's medical and health sector, consistently focusing on uncovering high-quality innovative forces in Chinese healthcare. This year’s selection centers on "the exhibition, trading, and empowerment of innovative assets in China's healthcare industry," officially launching in December 2025. It received over 1,000 enterprise applications, with broad coverage and extremely high industry participation. The selection criteria for this list have been optimized to focus on high-potential, high-momentum innovative companies, using financing activities since 2023 as the basic threshold to filter out active market players in accelerated growth phases. The list covers three core areas: innovative medical devices, innovative pharmaceuticals, and innovative health services. SIGNET was included in the Innovative Health Services and Industry Chain Services list, which was upgraded by merging two sub-lists, placing greater emphasis on evaluating enterprises' long-term growth potential and industrial service value. Companies on the list are predominantly top-tier forces that have matured through market experience.

This selection not only represents a high recognition of SIGNET's technological innovation, clinical transformation capabilities, and growth potential but also demonstrates the industry value of the "Organoid + AI" China-original R&D model. In the future, Signet Therapeutics will continue to focus on innovative R&D, accelerate the implementation of new drug pipelines, and make China-original anti-cancer drugs benefit more patients.

SIGNET is a pioneer in the global "organoid + AI" empowered innovative targeted drug R&D model, as well as a national high-tech enterprise and a specialized and new enterprise. The company's founding team is composed of outstanding talents from top institutions such as Harvard University, MIT, and the Chinese Academy of Sciences. As first/corresponding authors, they have published more than 20 groundbreaking research papers on gastric cancer, esophageal cancer, and other tumors in journals with an impact factor exceeding 20, such as Nature, Nature Medicine, and Cancer Cell, making them a global leader in the field of gastric and esophageal cancer research. Since its establishment in Shenzhen at the end of 2020, the company has completed nearly 300 million yuan in financing and project funding, and holds more than 40 core intellectual properties.

The company currently has multiple First-in-class drug pipelines and an organoid service platform. Its core pipeline, SIGX1094, is the world's first targeted drug for diffuse gastric cancer. It has successively obtained IND approval from the U.S. FDA and China NMPA, and received Orphan Drug Designation (ODD) and Fast Track Designation (FTD) from the U.S. FDA. In August 2025, this drug was nominated for the Galien Award, known as the "Nobel Prize of the pharmaceutical industry." It is currently undergoing Phase I clinical trials at Peking University Cancer Hospital and will soon enter Phase II clinical trials. This pipeline is also the world’s first drug to be advanced to the clinical stage through an "organoid + AI" technology platform. The second drug pipeline, SIGX2649, is a pan-TEAD inhibitor targeting the key downstream effector of the Hippo signaling pathway. There are currently no marketed drugs for this target, and it has already obtained IND approval from the U.S. FDA. The organoid service platform not only serves the company's own drug pipelines but also actively empowers large pharmaceutical enterprises in new drug development. Collaborative institutions include Shenzhen Second People's Hospital, the University of Hong Kong, the Hong Kong University of Science and Technology, Shenzhen BioRay Pharma, and Genuine Biotech, contributing to the birth of more innovative drugs.

Since its establishment at the end of 2020, the company's forward-looking strategic layout of an "Organoid+AI"-powered technology system for innovative targeted cancer drug development has gained international authoritative recognition. It was featured on the homepage of Fierce Biotech, a globally renowned biotech media outlet, and hailed as the "NEXT Generation" paradigm for cancer drug development. In April 2025, the U.S. FDA officially issued a statement explicitly supporting the gradual replacement of traditional animal testing with organoid and AI technologies, fully validating the foresight and scientific rigor of the company’s technical layout from four years prior.